These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 33130062)

  • 1. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
    Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
    Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.
    Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ
    Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Progress of Disulfide Bond Based Tumor Microenvironment Targeted Drug Delivery System.
    Ma W; Wang X; Zhang D; Mu X
    Int J Nanomedicine; 2024; 19():7547-7566. PubMed ID: 39071505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-targeted theranostic nanomedicines against cancer.
    Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
    J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
    Linton SS; Sherwood SG; Drews KC; Kester M
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):208-22. PubMed ID: 26153136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites.
    Attia MF; Anton N; Wallyn J; Omran Z; Vandamme TF
    J Pharm Pharmacol; 2019 Aug; 71(8):1185-1198. PubMed ID: 31049986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
    Cadete A; Alonso MJ
    Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics.
    Bose RJ; Paulmurugan R; Moon J; Lee SH; Park H
    Drug Discov Today; 2018 Apr; 23(4):891-899. PubMed ID: 29426004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer nanomedicines: so many papers and so few drugs!
    Venditto VJ; Szoka FC
    Adv Drug Deliv Rev; 2013 Jan; 65(1):80-8. PubMed ID: 23036224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress.
    Barkat HA; Das SS; Barkat MA; Beg S; Hadi HA
    Future Oncol; 2020 Dec; 16(35):2959-2979. PubMed ID: 32805124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
    Nakamura Y; Mochida A; Choyke PL; Kobayashi H
    Bioconjug Chem; 2016 Oct; 27(10):2225-2238. PubMed ID: 27547843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.